Clinical Trials Logo

Brain Metastasis clinical trials

View clinical trials related to Brain Metastasis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02425072 Withdrawn - Clinical trials for Small Cell Lung Cancer

NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

Start date: April 2016
Phase: Phase 2
Study type: Interventional

The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients.

NCT ID: NCT02328300 Withdrawn - Brain Metastases Clinical Trials

FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions

Start date: May 7, 2014
Phase:
Study type: Observational

This is a single arm, single center study of 15 patients with brain lesions being treated at UNC Hospitals. Subjects will undergo one (1) FLT-PET-MRI scan before their scheduled surgical biopsy of their brain lesion(s).

NCT ID: NCT01913067 Withdrawn - Breast Cancer Clinical Trials

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

CRANIAL
Start date: September 2013
Phase: Phase 2
Study type: Interventional

A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer (NSCLC). OBJECTIVES: Primary: The purpose of this study is to determine if cabazitaxel can induce a reduction in the size brain metastasis in metastatic HER2-negative breast cancer and NSCLC with brain metastasis who were not previously treated with whole brain irradiation or require immediate brain irradiation. Secondary: - To determine the effect of cabazitaxel on the time to initiating whole brain irradiation or radiosurgery - To determine the effect of cabazitaxel on the time to developing neurological symptoms - To determine the effect of cabazitaxel on the time to disease progression in the brain - To determine the effect of cabazitaxel on the time to disease progression outside the brain. This will be evaluated separately for the breast and NSCLC cohorts To determine the objective extra-cranial response (if applicable). This will be evaluated separately in the breast and NSCLC cohorts - To determine the safety of cabazitaxel